Sartorius AGSARTF 84 EBIT per Share is $8.52 as of Mar. 2026. GuruFocus rates SARTF with a GF Score™ of 84/100 and a GF Value™ of $234.29 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Sartorius AG ranks worse than 84.49% on this metric.
Sartorius AG's EBIT per Share for the
three
months ended in Mar. 2026 was $2.90.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $8.52.
During the past 12 months, the average EBIT per Share Growth Rate of Sartorius AG was 30.10% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -20.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -7.00% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 12.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Sartorius AG's EBIT per Share or its related term are showing as below:
SARTF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -22.5 Med: 19.9 Max: 54.6
Current: -20.9
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Sartorius AG was 54.60% per year. The lowest was -22.50% per year. And the median was 19.90% per year.
SARTF's 3-Year EBIT Growth Rate is ranked worse than 84.49% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.65
vs SARTF: -20.90
Sartorius AG's EBIT for the
three
months ended in Mar. 2026 was $201 Mil.
Sartorius AG (OTCPK:SARTF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Sartorius AG EBIT per Share Related Terms
Sartorius AG EBIT per Share Historical Data
* Premium members only.
The historical data trend for Sartorius AG's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.52
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius AG (SARTF) has a EBIT per Share of $8.52 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sartorius AG and its competitors. According to the industry distribution chart, Sartorius AG ranks #583 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 84.5%.
Is Sartorius AG's EBIT per Share too high?
Sartorius AG's current EBIT per Share is $8.52. The Medical Devices & Instruments industry median EBIT per Share is 9.65. Sartorius AG's value of $8.52 is 11.7% below this industry median. Based on the distribution chart, Sartorius AG ranks #583 out of 690 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sartorius AG has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's EBIT per Share compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #583 out of 690 companies for EBIT per Share. This places Sartorius AG in the lower half of its industry. The industry median EBIT per Share is 9.65. Sartorius AG's value of $8.52 is 11.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.65, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current EBIT per Share of $8.52 is 11.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sartorius AG and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current EBIT per Share is $8.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $234.29, compared to a current price of $212.80 — trading 9.2% below its estimated fair value. The current EBIT per Share is $8.52 and 11.7% below the Medical Devices & Instruments industry median of 9.65. Sartorius AG's overall GF Score™ is 84/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Sartorius AG (SARTF), the current EBIT per Share is $8.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $212.80 is trading 9.2% below its estimated GF Value™ of $234.29.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for SARTF:
EBIT per Share: $8.52
GF Value™: $234.29 vs. price of $212.80 (9.2% below fair value)
Industry Position: 11.7% below the Medical Devices & Instruments median (#583 of 690)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
84GF Score
Get the complete analysis for SARTF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
